β-adrenergic receptor induction in HeLa cells: Synergistic effect of 5-azacytidine and butyrate

https://doi.org/10.1016/S0006-291X(82)80067-3Get rights and content

Summary

We have described the induction of β-adrenergic receptors by butyrate in HeLa cells. Here we report preliminary results showing that β-adrenergic receptors can be induced to comparable levels by the nucleoside analogue 5-azacytidine. More importantly, sequential exposure to the two compounds has a strong synergistic effect; 5-azacytidine treatment for 24 hr followed by 24 hr exposure to butyrate results in receptor induction to levels 2 to 3 times greater than the sum of those found with butyrate and 5-azacytidine alone. Our results imply that induction of β-adrenergic receptors in HeLa by butyrate and 5-azacytidine may involve separate mechanisms.

References (20)

  • SchneiderF.H.

    Biochem. Pharmac.

    (1976)
  • LederA. et al.

    Cell

    (1975)
  • BoffaL.C. et al.

    J. Biol. Chem.

    (1981)
  • JonesP.A. et al.

    Cell

    (1980)
  • HarrisM.

    Cell

    (1982)
  • CreusotF. et al.

    J. Biol. Chem.

    (1982)
  • CompereS.J. et al.

    Cell

    (1981)
  • DerC.J. et al.

    Cell

    (1981)
  • HenneberryR.C. et al.

    Exp. Cell Res.

    (1976)
  • TallmanJ.F. et al.

    Biochim. Biophys. Acta

    (1978)
There are more references available in the full text version of this article.

Cited by (31)

  • Efficacy of combined epigenetic therapies

    2015, Drug Discovery in Cancer Epigenetics
  • Keynote review: Chromatin control and cancer-drug discovery: Realizing the promise

    2006, Drug Discovery Today
    Citation Excerpt :

    Drugs that inhibit DNA methyltransferase activity, such as 5-azacytidine and decitabine, reactivate methylation-dependent silenced genes in tumours and some of these agents have been evaluated in clinical trials [122]. Reports vary on their clinical activity, both as stand-alone agents and combination therapies [60,129–133]. Toxicity is a long-standing concern and, therefore, recent advances have focused on less toxic compounds with demethylating activity [134,135].

View all citing articles on Scopus
View full text